Keya Medical announced that it has completed a $30 Million Series C Funding Round led by IDG Capital, with participation from investors Alwin Capital, Source Code Capital, and Tasly Group.
We have compiled a list of free virtual events hosted by professional organizations that will take place in November, covering topics in cardiology, radiology, and AI.
Examine the current challenges for coronary CTA reimbursement, the potential effects it will have on patient care, and what medical imagers can do to help improve reimbursement moving forward.
On Oct. 17 and 18, the Chengdu Science and Technology Bureau hosted the 2020 DEMO China Innovation Finals, bringing together leading companies across the country.
Dr. Kunlin Cao, President of Keya Medical R&D, participated in the Cardiovascular Disease Imaging Forum at QICCD 2020 alongside Dr. Pengfei Zhang of Shangdong University.
Dr. Kunlin Cao delivered a keynote address at the China AI in Medical Imaging Conference on Keya Medical’s experience bringing AI-powered medical imaging solutions to clinical use.
Recent research demonstrates applications for CCTA to be used as the default test for evaluating patients with stable chest pain.
On Sept. 18, Keya Medical was recognized as the winner of of China’s Most Promising Company award because of its leading R&D team and innovative cardiovascular product line.
On Sept. 10, Keya Medical was invited to deliver an academic lecture to more than 130 imaging departments in honor of the newly established Northern Jiangsu People’s Hospital Medical Imaging Alliance.
Dr. Xinyang Hu delivered a special lecture during QICC 2020 on the clinical significance of non-invasive CT-FFR.
The European Society of Cardiology (ESC) Congress 2020 revealed opportunities and challenges in cardiovascular imaging AI.
ESC Updated Guidelines on Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation
The European Society of Cardiology published new clinical practice guidelines on managing acute coronary syndromes in patients.